文献速递帕金森病与运动障碍神经肌肉病

线粒体ATP合酶变异导致多变的神经系统表型

Variants in Mitochondrial ATP Synthase Cause Variable Neurologic Phenotypes.
PubMed 文献 · Ann Neurol · 2022-01-20

研究对2962例线粒体病和/或肌张力障碍患者行全外显子测序,发现10例携带核编码ATP合酶亚基基因双等位或新发单等位变异,临床表现高度异质,从自发缓解的肌张力低下到癫痫早期死亡不等,肌张力障碍常见(7/10)。

要点

  • ATP5F1E、ATP5PO、ATP5F1A、ATP5MC3变异可致线粒体ATP合酶相关神经系统表型。
  • 临床谱从肌张力低下自发缓解(1/10)到癫痫早期死亡(1/10)不等。
  • 肌张力障碍常见(7/10),但原文指出可能反映 ascertainment bias(确认偏倚)。

核心结论

  • 结果证实ATP合酶核基因缺陷在神经发育和神经退行性表型中具有此前未被认识的作用。

研究设计与样本

  • 对2962例诊断为线粒体病和/或肌张力障碍的患者队列行全外显子测序,并结合国际合作识别ATP合酶编码基因的有害变异。
  • 对患者成纤维细胞进行转录组和蛋白质组分析,并用5例患者的细胞和组织检测ATP合酶完整性和活性。

主要发现

  • 共报告10例携带核编码ATP合酶亚基基因双等位或新发单等位变异的个体。
  • 3例无亲缘关系患者携带相同的ATP5F1E纯合错义突变(包括1例已发表病例)。
  • 1例患者发现ATP5PO内含子剪接破坏性改变与无义变异构成复合杂合。
  • 3例患者携带ATP5F1A新发杂合错义变异,另3例携带ATP5MC3新发杂合错义改变。
  • 免疫组化、蛋白质组和/或免疫印迹显示ATP5F1E和ATP5PO突变相关的ATP合酶量显著减少;酶学试验和/或免疫印迹在携带ATP5F1A-p.Arg207His、ATP5MC3-p.Gly79Val和ATP5MC3-p.Asn106Lys的患者样本中证实活性降低和/或组装缺陷。

关键数值与推荐

  • 临床表型异质,从肌张力低下自发缓解(1/10)到癫痫早期死亡(1/10)或持续异常(运动障碍、发育迟缓、智力障碍、高乳酸血症及其他神经和系统特征)。
  • 肌张力障碍常见(7/10),但原文指出可能反映确认偏倚。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文指出肌张力障碍常见(7/10)可能反映确认偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: ATP synthase (ATPase) is responsible for the majority of ATP production. Nevertheless, disease phenotypes associated with mutations in ATPase subunits are extremely rare. We aimed at expanding the spectrum of ATPase-related diseases. METHODS: Whole-exome sequencing in cohorts with 2,962 patients diagnosed with mitochondrial disease and/or dystonia and international collaboration were used to identify deleterious variants in ATPase-encoding genes. Findings were complemented by transcriptional and proteomic profiling of patient fibroblasts. ATPase integrity and activity were assayed using cells and tissues from 5 patients. RESULTS: We present 10 total individuals with biallelic or de novo monoallelic variants in nuclear ATPase subunit genes. Three unrelated patients showed the same homozygous missense ATP5F1E mutation (including one published case). An intronic splice-disrupting alteration in compound heterozygosity with a nonsense variant in ATP5PO was found in one patient. Three patients had de novo heterozygous missense variants in ATP5F1A, whereas another 3 were heterozygous for ATP5MC3 de novo missense changes. Bioinformatics methods and populational data supported the variants' pathogenicity. Immunohistochemistry, proteomics, and/or immunoblotting revealed significantly reduced ATPase amounts in association to ATP5F1E and ATP5PO mutations. Diminished activity and/or defective assembly of ATPase was demonstrated by enzymatic assays and/or immunoblotting in patient samples bearing ATP5F1A-p.Arg207His, ATP5MC3-p.Gly79Val, and ATP5MC3-p.Asn106Lys. The associated clinical profiles were heterogeneous, ranging from hypotonia with spontaneous resolution (1/10) to epilepsy with early death (1/10) or variable persistent abnormalities, including movement disorders, developmental delay, intellectual disability, hyperlactatemia, and other neurologic and systemic features. Although potentially reflecting an ascertainment bias, dystonia was common (7/10). INTERPRETATION: Our results establish evidence for a previously unrecognized role of ATPase nuclear-gene defects in phenotypes characterized by neurodevelopmental and neurodegenerative features. ANN NEUROL 2022;91:225-237.

来源:Ann Neurol,查看原文。版权归原作者所有。

引用

  1. Zech M, Kopajtich R, Steinbrücker K, et al. Variants in Mitochondrial ATP Synthase Cause Variable Neurologic Phenotypes. Ann Neurol. 2022. PMID: 34954817. doi:10.1002/ana.26293

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。